ELDN
Eledon Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology · US
$2.16
+1.41%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$2.15
From 52W high−50.46%
Volume1.05M
Market cap$175.52M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataOct 19, 2026
Open
$2.15
From 52W high
−50.46%
Volume
1.05M
Market cap
$175.52M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−1.6x
P/E (TTM)
—
RSI (14)
30.8
MomentumView details →
1D Return
+1.41%
YTD Return
+46.64%
SummaryUpdated Jun 1, 2026
Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) is a clinical-stage biopharmaceutical company founded in 2014 and headquartered in Irvine, California. Originally known as Novus Therapeutics, Inc., the company underwent a strategic transformation and changed its name to Eledon Pharmaceuticals in January 2021. The company focuses on developing innovative medicines for patients living with autoimmune diseases, amyotrophic lateral sclerosis (ALS), and those requiring organ or cell-based transplants.
Similar companies
Latest newsMore news →
Eledon Pharmaceuticals presented updated long-term Phase 2 BESTOW extension study results for tegoprubart at the International Congress of The Transplantation Society, reporting higher kidney function versus tacrolimus through 24 months.28d agoEledon Pharmaceuticals dosed the first patients under compassionate use of tegoprubart in highly sensitized patients with pre-existing antibodies receiving a kidney transplant.47d agoEledon Pharmaceuticals enrolled the first patients in a new investigator-initiated study of tegoprubart in patients with renal dysfunction receiving an islet cell transplant.47d ago